A Review of Cardiovascular Diseases in Substance Use Disorders: Current Knowledge and Future Perspectives

Document Type : Review Article(s)

Authors

1 Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran

2 Department of Cardiovascular Medicine, Kashan University of Medical Sciences, Kashan, Iran

3 Social Determinants of Health (SDH) Research Center, Kashan University of Medical Sciences, Kashan, Iran

4 Clinical Research Development Unit-Matini/Kargarnejad Hospital, Kashan University of Medical Sciences, Kashan, Iran

10.34172/ahj.1722

Abstract

Background: Nowadays, the emergence of new types of substances and the growing prevalence of addiction have made substance use a global challenge for public health. At the same time, the complications of substance use are observed in various physical and psychological dimensions, including a range of acute and chronic cardiovascular diseases. This issue is significant, as many young people are affected by these complications. Therefore, understanding these complications is both important and practical.
Methods: Clinical articles related to the acute and chronic cardiovascular effects of the main groups of substances were searched in the PubMed, Web of Science, Scopus, and Google Scholar databases from 2015 to 2025.
Results: Evidence of cardiovascular complications related to the use of major substance groups, including opioids, stimulants, nicotine, caffeine, alcohol, cannabinoids, tranquilizers, and anabolic steroids, has been obtained. Some of this evidence only indicates an increase in risk factors for the disease, while some reports also point to acute and chronic cardiac complications and even cardiorespiratory arrest and death.
Conclusion: Given the cardiac complications of substance use, cessation and treatment should be personalized to each patient’s circumstances.

Highlights

 Amir Ghaderi(Google Scholar)(Pubmed)

Keywords

References

  1. Nawi AM, Ismail R, Ibrahim F, Hassan MR, Manaf MR, Amit N, et al. Risk and protective factors of drug abuse among adolescents: a systematic review. BMC Public Health. 2021;21(1):2088. doi: 10.1186/s12889-021-11906-2.
  2. Ciucă Anghel DM, Nițescu GV, Tiron AT, Guțu CM, Baconi DL. Understanding the mechanisms of action and effects of drugs of abuse. Molecules. 2023;28(13):4969. doi: 10.3390/ molecules28134969.
  3. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.
  4. Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361-71. doi: 10.1016/j.jacc.2022.11.005.
  5. Zhao J, Chen H, Zhuo C, Xia S. Cannabis use and the risk of cardiovascular diseases: a mendelian randomization study. Front Cardiovasc Med. 2021;8:676850. doi: 10.3389/ fcvm.2021.676850.
  6. Evans K, Wu P, Mamas MA, Irwin C, Kang P, Perlow JH, et al. Substance use in pregnancy and its association with cardiovascular events. JACC Adv. 2023;2(8):100619. doi: 10.1016/j.jacadv.2023.100619.
  7. Lahiri A, Jha SS, Chakraborty A. Addiction habits in a rural cohort of injection drug users and effects on serum lipid profile: analysis of a repeated measures study from an eastern state of India. Natl Med J India. 2023;36(3):150-6. doi: 10.25259/nmji_1_21.
  8. Masoudkabir F, Shafiee A, Heidari A, Hosseini Mohammadi NS, Tavakoli K, Jalali A, et al. Epidemiology of substance and opium use among adult residents of Tehran; a comprehensive report from Tehran cohort study (TeCS). BMC Psychiatry. 2024;24(1):132. doi: 10.1186/s12888-024-05561-1.
  9. Najafipour H, Masoumi M, Amirzadeh R, Rostamzadeh F, Foad R, Shadkam Farrokhi M. Trends in the prevalence and incidence of opium abuse and its association with coronary artery risk factors in adult population in Iran: findings from Kerman coronary artery disease risk factors study. Iran J Med Sci. 2022;47(4):328-37. doi: 10.30476/ ijms.2021.89898.2065.
  10. Mason JW, Schwertschlag US, Klutzaritz V, Canafax DM. Electrocardiographic and cardiovascular diagnostic characteristics of patients receiving long-term opioid therapy for pain. J Opioid Manag. 2014;10(2):103-9. doi: 10.5055/ jom.2014.0199.
  11. Singleton JH, Abner EL, Akpunonu PD, Kucharska-Newton AM. Association of nonacute opioid use and cardiovascular diseases: a scoping review of the literature. J Am Heart Assoc. 2021;10(13):e021260. doi: 10.1161/jaha.121.021260.
  12. Behzadi M, Joukar S, Beik A. Opioids and cardiac arrhythmia: a literature review. Med Princ Pract. 2018;27(5):401-14. doi: 10.1159/000492616.
  13. Zahmatkesh M, Kadkhodaee M, Salarian A, Seifi B, Adeli S. Impact of opioids on oxidative status and related signaling pathways: an integrated view. J Opioid Manag. 2017;13(4):241-51. doi: 10.5055/jom.2017.0392.
  14. Valois-Santos NT, de Almeida RB, de Jesus Almeida Alves Jacques I, de Paula Santos D, de Brito E Silva KS, Nappo SA, et al. Association between alcohol and crack: prevalence, effects, associated factors and experiences of combined use. PLoS One. 2021;16(9):e0256414. doi: 10.1371/journal. pone.0256414.
  15. Larsson SC, Burgess S, Mason AM, Michaëlsson K. Alcohol consumption and cardiovascular disease: a Mendelian randomization study. Circ Genom Precis Med. 2020;13(3):e002814. doi: 10.1161/circgen.119.002814.
  16. Li Z, Gu M, Zaparte A, Fu X, Mahen K, Mrdjen M, et al. Alcohol-induced gut microbial reorganization and associated overproduction of phenylacetylglutamine promotes cardiovascular disease. Nat Commun. 2024;15(1):10788. doi: 10.1038/s41467-024-55084-2.
  17. Verma N, Rastogi S, Chia YC, Siddique S, Turana Y, Cheng HM, et al. Non-pharmacological management of hypertension. J Clin Hypertens (Greenwich). 2021;23(7):1275-83. doi: 10.1111/jch.14236.
  18. Hernández-Pérez A, García-Gómez L, Robles-Hernández R, Thirión-Romero I, Osio-Echánove J, Rodríguez-Llamazares S, et al. Addiction to tobacco smoking and vaping. Rev Invest Clin. 2023;75(3):158-68. doi: 10.24875/ric.23000117.
  19. Alimohammadi M, Jafari-Mansoorian H, Hashemi SY, Momenabadi V, Ghasemi SM, Karimyan K. Review on the implementation of the Islamic Republic of Iran about tobacco control, based on MPOWER, in the framework convention on tobacco control by the World Health Organization. Addict Health. 2017;9(3):183-9.
  20. Mahdaviazad H, Foroutan R, Masoompour SM. Prevalence of tobacco smoking and its socioeconomic determinants: tobacco smoking and its determinants. Clin Respir J. 2022;16(3):208- 15. doi: 10.1111/crj.13470.
  21. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376-414. doi: 10.1016/j. jacc.2019.03.009.
  22. Simani M, Ghaderi A, Saffari I, Yazdani A, Rajabi Moghaddam H, Bagherian E. Evaluation of 10 years atherosclerotic cardiovascular risk, vitamin D and metabolic profiles in smokers: atherosclerotic cardiovascular disease and smokers. Int J Med Toxicol Forensic Med. 2025;15(2):E47674. doi: 10.32598/ijmtfm.v15i02.47674.
  23. Benowitz NL, Burbank AD. Cardiovascular toxicity of nicotine: implications for electronic cigarette use. Trends Cardiovasc Med. 2016;26(6):515-23. doi: 10.1016/j.tcm.2016.03.001.
  24. Banks E, Yazidjoglou A, Brown S, Nguyen M, Martin M, Beckwith K, et al. Electronic cigarettes and health outcomes: umbrella and systematic review of the global evidence. Med J Aust. 2023;218(6):267-75. doi: 10.5694/mja2.51890.
  25. Zhou A, Hyppönen E. Long-term coffee consumption, caffeine metabolism genetics, and risk of cardiovascular disease: a prospective analysis of up to 347,077 individuals and 8368 cases. Am J Clin Nutr. 2019;109(3):509-16. doi: 10.1093/ ajcn/nqy297.
  26. Abdoli F, Davoudi M, Momeni F, Djafari F, Dolatshahi B, Hosseinzadeh S, et al. Estimate the prevalence of daily caffeine consumption, caffeine use disorder, caffeine withdrawal and perceived harm in Iran: a cross-sectional study. Sci Rep. 2024;14(1):7644. doi: 10.1038/s41598-024-58496-8.
  27. Turnbull D, Rodricks JV, Mariano GF, Chowdhury F. Caffeine and cardiovascular health. Regul Toxicol Pharmacol. 2017;89:165-85. doi: 10.1016/j.yrtph.2017.07.025.
  28. Temple JL, Bernard C, Lipshultz SE, Czachor JD, Westphal JA, Mestre MA. The safety of ingested caffeine: a comprehensive review. Front Psychiatry. 2017;8:80. doi: 10.3389/ fpsyt.2017.00080.
  29. Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7(1):16. doi: 10.1038/s41572-021-00247-4.
  30. Nazarzadeh M, Bidel Z, Mosavi Jarahi A, Esmaeelpour K, Menati W, Shakeri AA, et al. Prevalence of cannabis lifetime use in Iranian high school and college students: a systematic review, meta-analyses, and meta-regression. Am J Mens Health. 2015;9(5):397-409. doi: 10.1177/1557988314546667.
  31. Drummer OH, Gerostamoulos D, Woodford NW. Cannabis as a cause of death: a review. Forensic Sci Int. 2019;298:298- 306. doi: 10.1016/j.forsciint.2019.03.007.
  32. Varga ZV, Ferdinandy P, Liaudet L, Pacher P. Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309(9):H1453-67. doi: 10.1152/ ajpheart.00554.2015.
  33. Farrell M, Martin NK, Stockings E, Bórquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019;394(10209):1652- 67. doi: 10.1016/s0140-6736(19)32230-5.
  34. Abedi Gheshlaghi L, Sharifi H, Darabi M, Chegeni M, Khalili M, Noroozi A, et al. Prevalence of amphetamine-type stimulants use in Iran: a systematic review and meta-analysis. J Subst Use. 2021;26(6):569-85. doi: 10.1080/14659891.2021.1879289.
  35. Xue M, Li F, Feng S, Liu S, Gao L. A rare incidence of acute ischaemic stroke with reversible middle cerebral artery occlusion in a methamphetamine addict: case report. Heliyon. 2024;10(8):e29425. doi: 10.1016/j.heliyon.2024.e29425.
  36. Kevil CG, Goeders NE, Woolard MD, Bhuiyan MS, Dominic P, Kolluru GK, et al. Methamphetamine use and cardiovascular disease: in search of answers. Arterioscler Thromb Vasc Biol. 2019;39(9):1739-46. doi: 10.1161/atvbaha.119.312461.
  37. Dugo E, Barison A, Todiere G, Grigoratos C, Aquaro GD. Cardiac magnetic resonance in cocaine-induced myocardial damage: cocaine, heart, and magnetic resonance. Heart Fail Rev. 2022;27(1):111-8. doi: 10.1007/s10741-020-09983-3.
  38. Gagnon LR, Sadasivan C, Perera K, Oudit GY. Cardiac complications of common drugs of abuse: pharmacology, toxicology, and management. Can J Cardiol. 2022;38(9):1331- 41. doi: 10.1016/j.cjca.2021.10.008.
  39. Schepis TS, Wastila L, McCabe SE. Prescription tranquilizer/ sedative misuse motives across the US population. J Addict Med. 2021;15(3):191-200. doi: 10.1097/adm.0000000000000736.
  40. Abbasi-Ghahramanloo A, Khodadost M, Moradpour F, Karimirad MR, Kamali R, Ziarati F. Prevalence of nonmedical use of prescription-type opioids, methylphenidate, and sedative-hypnotics among university students in the south of Iran: a regression analysis. Electron Physician. 2018;10(6):6981-7. doi: 10.19082/6981.
  41. Balon R, Rafanelli C, Sonino N. Benzodiazepines: a valuable tool in the management of cardiovascular conditions. Psychother Psychosom. 2018;87(6):327-30. doi: 10.1159/000493015.
  42. Izrailtyan I, Qiu J, Overdyk FJ, Erslon M, Gan TJ. Risk factors for cardiopulmonary and respiratory arrest in medical and surgical hospital patients on opioid analgesics and sedatives. PLoS One. 2018;13(3):e0194553. doi: 10.1371/journal. pone.0194553.
  43. Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333-40. doi: 10.1111/joim.12850.
  44. El Osta R, Almont T, Diligent C, Hubert N, Eschwège P, Hubert J. Anabolic steroids abuse and male infertility. Basic Clin Androl. 2016;26:2. doi: 10.1186/s12610-016-0029-4.
  45. Selk-Ghaffari M, Shab-Bidar S, Halabchi F. The prevalence of anabolic-androgenic steroid misuse in Iranian athletes: a systematic review and meta-analysis. Iran J Public Health. 2021;50(6):1120-34. doi: 10.18502/ijph.v50i6.6411.
  46. Windfeld-Mathiasen J, Heerfordt IM, Dalhoff KP, Andersen JT, Andersen MA, Johansson KS, et al. Cardiovascular disease in anabolic androgenic steroid users. Circulation. 2025;151(12):828-34. doi: 10.1161/ circulationaha.124.071117.
  47. Heiland CE, Schickel Y, Lehtihet M, Börjesson A, Ekström L. Supra-physiological doses of anabolic androgenic steroids impact erythropoietin and blood parameters. Drug Test Anal. 2023;15(6):599-604. doi: 10.1002/dta.3452.
  48. Middlekauff HR, Cooper ZD, Strauss SB. Drugs of misuse: focus on vascular dysfunction. Can J Cardiol. 2022;38(9):1364-77. doi: 10.1016/j.cjca.2022.04.011.
  49. Vallecillo G, Pedro-Botet J, Fernandez S, Román I, Elosua R, Camps A, et al. High cardiovascular risk in older patients with opioid use disorder: differences with the general population. Drug Alcohol Rev. 2022;41(5):1078-84. doi: 10.1111/ dar.13449.
  50. Ozen G, Pedro S, Michaud K. Major adverse cardiovascular events and mortality with opioids versus NSAIDs initiation in patients with rheumatoid arthritis. Ann Rheum Dis. 2023;82(11):1487-94. doi: 10.1136/ard-2023-224339.
  51. Agudelo-Ochoa GM, Pulgarín-Zapata IC, Velásquez- Rodriguez CM, Duque-Ramírez M, Naranjo-Cano M, Quintero-Ortiz MM, et al. Coffee consumption increases the antioxidant capacity of plasma and has no effect on the lipid profile or vascular function in healthy adults in a randomized controlled trial. J Nutr. 2016;146(3):524-31. doi: 10.3945/ jn.115.224774.
  52. Zheng H, Lin F, Xin N, Yang L, Zhu P. Association of coffee, tea, and caffeine consumption with all-cause risk and specific mortality for cardiovascular disease patients. Front Nutr. 2022;9:842856. doi: 10.3389/fnut.2022.842856.
  53. Biddinger KJ, Emdin CA, Haas ME, Wang M, Hindy G, Ellinor PT, et al. Association of habitual alcohol intake with risk of cardiovascular disease. JAMA Netw Open. 2022;5(3):e223849. doi: 10.1001/jamanetworkopen.2022.3849.
  54. Shao L, Chen Y, Zhao Z, Luo S. Association between alcohol consumption and all-cause mortality, cardiovascular disease, and chronic kidney disease: a prospective cohort study. Medicine (Baltimore). 2024;103(27):e38857. doi: 10.1097/ md.0000000000038857.
  55. Allagbé I, Zeller M, Thomas D, Airagnes G, Limosin F, Boussadi A, et al. Cardiovascular risk among patients who smoke: risk profiles and differences by sex. Am J Prev Med. 2022;63(5):800-8. doi: 10.1016/j.amepre.2022.04.028.
  56. George J, Hussain M, Vadiveloo T, Ireland S, Hopkinson P, Struthers AD, et al. Cardiovascular effects of switching from tobacco cigarettes to electronic cigarettes. J Am Coll Cardiol. 2019;74(25):3112-20. doi: 10.1016/j.jacc.2019.09.067.
  57. Tattersall MC, Hughey CM, Piasecki TM, Korcarz CE, Hansen KM, Ott NR, et al. Cardiovascular and pulmonary responses to acute use of electronic nicotine delivery systems and combustible cigarettes in long-term users. Chest. 2023;164(3):757-69. doi: 10.1016/j.chest.2023.03.047.
  58. Duncan MS, Freiberg MS, Greevy RA Jr, Kundu S, Vasan RS, Tindle HA. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA. 2019;322(7):642-50. doi: 10.1001/jama.2019.10298.
  59. Khan S, Hanif A, Wilson MF. Ischaemic cardiomyopathy and embolic stroke in a young adult with suspected synthetic cannabinoid use. BMJ Case Rep. 2018;2018. doi: 10.1136/ bcr-2018-224755.
  60. Jeffers AM, Glantz S, Byers AL, Keyhani S. Association of cannabis use with cardiovascular outcomes among US adults. J Am Heart Assoc. 2024;13(5):e030178. doi: 10.1161/ jaha.123.030178.
  61. Alzeer AA, Suliman I, Altamimi M, Alshudukhi AM, Alzeer AA, Alwasidi EO. Acute myocardial infarction associated with amphetamine use and smoking in a young healthy individual. Cureus. 2023;15(12):e50323. doi: 10.7759/cureus.50323.
  62. Dalal S, Arustamyan M, Marmolejos G, Ramakrishna K. Delayed cardiomyopathy and cardiogenic shock due to intravenous methamphetamine use requiring hemodynamic support with veno-arterial extracorporeal membrane oxygenation. J Am Coll Emerg Physicians Open. 2020;1(2):117-9. doi: 10.1002/emp2.12027.
  63. Almalouf C, Hakobyan N, Yadav V, Gandhi A, Yadav R. Cardiac arrest (CA) as the initial presentation of cocaine-induced Takotsubo cardiomyopathy (TCM): a case report and review of literature. Cureus. 2023;15(5):e38525. doi: 10.7759/cureus.38525.
  64. Saeed S, Rotevatn S, Schjøtt J, Larsen TH. Acute myocardial injury in a patient with attention deficit hyperactivity disorder and history of substance abuse: a multimodality imaging point of view. J Cardiovasc Dev Dis. 2021;8(6):67. doi: 10.3390/ jcdd8060067.
  65. Kandukuru A, Sharma P, Verghese Gupta S, Nkembo A, Sutariya V. Cardiovascular adverse events associated with norepinephrine-dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System. Can J Physiol Pharmacol. 2024;102(12):709-19. doi: 10.1139/cjpp-2024-0128.
  66. Xie Y, Zhu S, Wu S, Liu C, Shen J, Jin C, et al. Hypnotic use and the risk of cardiovascular diseases in insomnia patients. Eur J Prev Cardiol. 2025;32(6):466-74. doi: 10.1093/eurjpc/ zwae263.
  67. Neupane S, Kalra F. Association of anabolic steroid use with hypertension and cardiomyopathy: a case study. Cureus. 2024;16(10):e71775. doi: 10.7759/cureus.71775.
  68. Thiblin I, Garmo H, Garle M, Holmberg L, Byberg L, Michaëlsson K, et al. Anabolic steroids and cardiovascular risk: a national population-based cohort study. Drug Alcohol Depend. 2015;152:87-92. doi: 10.1016/j. drugalcdep.2015.04.013.
  69. Domínguez F, Adler E, García-Pavía P. Alcoholic cardiomyopathy: an update. Eur Heart J. 2024;45(26):2294- 305. doi: 10.1093/eurheartj/ehae362.
  70. Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchía J, et al. Genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol. 2018;71(20):2293- 302. doi: 10.1016/j.jacc.2018.03.462.
Addiction & Health
Volume 17
Pages 1-16

Files

Share

How to cite

Statistics